HIGHLIGHTS
- who: Guanlan Xu and collaborators from the Comprehensive Diabetes Center, University ofBirmingham, Birmingham, AL, USA have published the paper: Exploratory study reveals far reaching systemic and cellular effects of verapamil treatment in subjects with type diabetes, in the Journal: NATURE COMMUNICATIONS NATURE COMMUNICATIONS
- what: This studies were aimed at addressing these questions using proteomics, transcriptomics, and pathophysiological approaches. The authors now show that verapamil reverses T1D associated increases in serum CHGA levels, proinflammatory interleukin-21 (IL-21) levels, and T-follicular-helper (Tfh) cell markers and promotes an anti-oxidative, anti-apoptotic and immunomodulatory gene_expression . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.